Rusfertide Reduces Phlebotomy Burden, Improves Disease-Related Symptoms in Polycythemia Vera

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the VERIFY trial, which evaluated treatment with the hepcidin mimetic rusfertide in patients with polycythemia vera. This abstract will be presented as LBA3 during the Plenary Session at the 2025 ASCO Annual Meeting. Read the full abstract: https://meetings.asco.org/abstracts-presentations/246466 For more on ASCO25, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 19, 2025_

Video Lainnya